Last reviewed · How we verify
doxorubicin HCL liposome; bevacizumab; carboplatin
doxorubicin HCL liposome; bevacizumab; carboplatin is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 2 development.
At a glance
| Generic name | doxorubicin HCL liposome; bevacizumab; carboplatin |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (PHASE1, PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE1)
- A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxorubicin HCL liposome; bevacizumab; carboplatin CI brief — competitive landscape report
- doxorubicin HCL liposome; bevacizumab; carboplatin updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about doxorubicin HCL liposome; bevacizumab; carboplatin
What is doxorubicin HCL liposome; bevacizumab; carboplatin?
doxorubicin HCL liposome; bevacizumab; carboplatin is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Who makes doxorubicin HCL liposome; bevacizumab; carboplatin?
doxorubicin HCL liposome; bevacizumab; carboplatin is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).
What development phase is doxorubicin HCL liposome; bevacizumab; carboplatin in?
doxorubicin HCL liposome; bevacizumab; carboplatin is in Phase 2.